The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K

This publication has 38 references indexed in Scilit:

• Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
  Blood Cancer Journal, 2013
• Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity
  AIDS, 2012
• The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo
  Haematologica, 2012
• Utility of mTOR Inhibition in Hematologic Malignancies
  The Oncologist, 2011
• Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome‐independent block of angiogenesis and matrix metalloproteinases
  International Journal of Cancer, 2010
• Targeting the translational machinery as a novel treatment strategy for hematologic malignancies
  Blood, 2010
• NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action
  Nitric Oxide, 2008
• Protein database searches using compositionally adjusted substitution matrices
  The FEBS Journal, 2005
• Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
  Nucleic Acids Research, 1997
• Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines
  FEBS Letters, 1994